Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 3/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16163652 | 0.89 | SMN1; SMN2 (0.44) | TNKSTNKS2OPRM1OPRD1SMN1; SMN2 | |
| SCHEMBL29472505 | 0.86 | NCOA1 (0.52) | TNKSTNKS2HTTNCOA1NCOA3 | |
| SCHEMBL19581218 | 0.85 | TNKS (0.52) | TNKSTNKS2OPRM1HTTNCOA1 | |
| SCHEMBL15955695 | 0.82 | TNKS (0.47) | TNKSTNKS2OPRM1HTTNCOA1 | |
| Hydrochloric Acid SCHEMBL20236145 | 0.80 | TAS2R14 (0.46) | TNKSTNKS2SMN1; SMN2POLB | |
| SCHEMBL20236710 | 0.80 | CA1 (0.46) | OPRM1OPRD1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL15957003 | 0.80 | ALDH1A1 (0.54) | TNKSTNKS2HTTSMN1; SMN2MLYCD | |
| SCHEMBL15962948 | 0.80 | ALDH1A1 (0.59) | TNKSTNKS2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22217671 | 0.79 | CA1 (0.45) | OPRM1OPRD1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL27359509 | 0.79 | TNKS (0.69) | TNKSTNKS2SMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| EP-2956441-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | The Scripps Research Institute (US) | 2015-12-23 | — | — | EP | disclosed |
| WO-2014127350-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | TNKS 3074/4885TNKS2 3264/4885OPRM1 151/4885 |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | TNKS 3074/4885TNKS2 3264/4885OPRM1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.